Skip to content

Study · Randomized controlled trial · n = 8 · 1998

5 results

Hemodynamic effects of the somatostatin analog lanreotide in humans: placebo-controlled, cross-over dose-ranging Echo-Doppler study.

Mottet C, Sieber CC, Nauer A, Drewe J, Fried R, Larsen F, Beglinger C

Hepatology (Baltimore, Md.)1 Apr 1998Cited by 14 (Europe PMC)

PMID9537429 (opens in a new tab)DOI10.1002/hep.510270405 (opens in a new tab)PepBankPUB-09537429
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy men, all lanreotide doses abolished food-stimulated superior mesenteric arterial hyperemia over 7 hours compared with placebo.

    In plain wordsIn healthy men, all lanreotide doses blocked the meal-induced increase in mesenteric blood flow compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseFood-stimulated superior mesenteric arterial hyperemia
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    50, 100, or 200 microg/h · intravenous · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    Lanreotide at all doses abolished food-stimulated splanchnic hyperemia both in the SMA and PV over 7 hours.
    2 context sentences
    Summary · context
    A dose-response curve was constructed in eight healthy male subjects in a placebo-controlled cross-over study.
    Summary · context
    On 4 different days, either 0 (placebo), 50, 100, or 200 microg/h of lanreotide was infused intravenously in random order, starting at 45 minutes for 7 hours.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy men, all lanreotide doses abolished food-stimulated portal venous hyperemia over 7 hours compared with placebo.

    In plain wordsIn healthy men, all lanreotide doses blocked the meal-induced increase in portal blood flow compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreaseFood-stimulated portal venous hyperemia
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    50, 100, or 200 microg/h · intravenous · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    Lanreotide at all doses abolished food-stimulated splanchnic hyperemia both in the SMA and PV over 7 hours.
    2 context sentences
    Summary · context
    A dose-response curve was constructed in eight healthy male subjects in a placebo-controlled cross-over study.
    Summary · context
    On 4 different days, either 0 (placebo), 50, 100, or 200 microg/h of lanreotide was infused intravenously in random order, starting at 45 minutes for 7 hours.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide blunted the fall in diastolic arterial pressure after food perfusion compared with placebo.

    In plain wordsIn healthy men, lanreotide reduced the meal-induced fall in diastolic blood pressure compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreasePostprandial diastolic pressure fall
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    50, 100, or 200 microg/h · intravenous · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    The fall in dBP and increase in HR after food perfusion were blunted under lanreotide.
    2 context sentences
    Summary · context
    A dose-response curve was constructed in eight healthy male subjects in a placebo-controlled cross-over study.
    Summary · context
    On 4 different days, either 0 (placebo), 50, 100, or 200 microg/h of lanreotide was infused intravenously in random order, starting at 45 minutes for 7 hours.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide blunted the heart rate increase after food perfusion compared with placebo.

    In plain wordsIn healthy men, lanreotide reduced the meal-induced heart rate increase compared with placebo.

    Peptide
    Lanreotide
    Outcome
    DecreasePostprandial heart rate increase
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    50, 100, or 200 microg/h · intravenous · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    The fall in dBP and increase in HR after food perfusion were blunted under lanreotide.
    2 context sentences
    Summary · context
    A dose-response curve was constructed in eight healthy male subjects in a placebo-controlled cross-over study.
    Summary · context
    On 4 different days, either 0 (placebo), 50, 100, or 200 microg/h of lanreotide was infused intravenously in random order, starting at 45 minutes for 7 hours.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy men, lanreotide did not modify renal artery resistance index.

    In plain wordsIn healthy men, lanreotide did not change renal artery resistance index compared with placebo.

    Peptide
    Lanreotide
    Outcome
    No significant changeRenal artery resistance index
    Study

    n = 8

    Comparator
    Placebo
    Outcome group
    Kidney function · Kidney and urinary
    Studied dose
    50, 100, or 200 microg/h · intravenous · 7 hoursAs given in this study (human).

    Source sentences

    Summary
    Food as well as lanreotide did not modify RA-RI.
    2 context sentences
    Summary · context
    A dose-response curve was constructed in eight healthy male subjects in a placebo-controlled cross-over study.
    Summary · context
    On 4 different days, either 0 (placebo), 50, 100, or 200 microg/h of lanreotide was infused intravenously in random order, starting at 45 minutes for 7 hours.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.